Our data revealed that downstream −1N in the PGC1α promoter is associated with higher adiposity and adverse health risk, whereas those individuals with an upstream −1N had lower adiposity and obesity-related risk for CVD. This evidence concerns the gene PPARGC1A and obesity disorder.